Biosynex

Equities

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 04:31:00 2024-04-19 am EDT			5-day change	1st Jan Change
4.97 ^EUR	-2.55%		+8.04%	-40.48%

2023	Biosynex: merger with Theradiag completed	CF
2023	Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Biosynex SA commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

June 16, 2021 at 12:43 pm EDT

Biosynex SA (ENXTPA:ALBIO) commences share repurchases on June 16, 2021, under the program mandated by the shareholders in the Annual General Meeting held on June 8, 2020. As per the mandate, the company is authorized to repurchase up to 10% of the share capital, for a total for €4.5 million. The shares will be repurchased at a price of €150 per share. The program will be valid for 18 months.

Latest news about Biosynex

Biosynex: merger with Theradiag completed	Dec. 18	CF
Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Biosynex Unit to Acquire US-based Biotech Qualigen	23-07-21	MT
Biosynex SA acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.	23-06-12	CI
Biosynex SA signed an agreement to acquire 57.33% interest in ProciseDx Inc. from NestlÃ© HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.	23-06-11	CI
Biosynex SA acquired Eye Care activity from LABORATOIRES INNOXA.	23-06-07	CI
Biosynex SA completed the acquisition of Chembio Diagnostics, Inc. from Perceptive Advisors LLC and others.	23-04-26	CI
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony...	23-04-21
Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Chembio Diagnostics Tender Offer Expiration Extended by Biosynex	23-04-13	MT
Biosynex Unit Extends Expiration Time of Tender Offer for Chembio Diagnostics Shares; Stock Rises	23-03-29	MT
Chembio Diagnostics Agrees to $17.2 Million Takeover by Biosynex; Shares Rise Pre-Bell	23-02-01	MT
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million.	23-01-30	CI
Biosynex SA entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. for $17.2 million.	23-01-30	CI
Biosynex Sa Extend Distribution Agreement with Credo Diagnostics Biomedical Pte Ltd	23-01-12	CI
Biosynex SA completed the acquisition of 40% stakes in Theradiag SA.	23-01-11	CI
Biosynex SA acquired 75% stake in Medkoncept A/S.	22-12-20	CI
Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-20	CI
Biosynex SA acquired Doc2u SAS on October 12, 2022.	22-10-11	CI
French Diagnostics Company Biosynex Offers to Take Over Theradiag	22-09-23	MT
Biosynex SA bid to acquire remaining 74.93% stakes in Theradiag SA.	22-09-22	CI
Biosynex SA agreed to acquire Bigix Pharma Srl.	22-09-21	CI
Biosynex SA alongside the two founders acquired Bhr Pharmaceuticals Limited.	22-05-22	CI
Biosynex SA acquired PrimaDiag SAS.	22-04-19	CI
Biosynex SA acquired Para'kito.	22-04-18	CI

Chart Biosynex

Duration

Period

More charts

Company Profile

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents. At the end of 2022, the group had one production site located in France. France accounts for 61.1% of net sales.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOSYNEX	-40.48%	58.52M
BIOMÉRIEUX	-2.29%	12.47B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.62%	6.99B
DIASORIN S.P.A.	-4.83%	5.1B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.68%	4.27B
LANTHEUS HOLDINGS, INC.	+0.53%	4.27B
10X GENOMICS, INC.	-48.27%	3.45B
ANDON HEALTH CO., LTD.	+7.09%	2.61B
VITROLIFE AB	-14.33%	2.08B
MYRIAD GENETICS, INC.	-3.40%	1.67B

Diagnostic & Testing Substances